Comes to Ue Car-T, the cure for blood cancers that uses the patient's cells – Medicine

After the green light in the United States, Europe also approves the first therapy for two blood cancers based on the technique & # 39; t Car-& # 39; , which involves the use of "trained" patient cells to recognize cancer cells.
The green disk for Kymriah comes from the Chmp, the Ema committee that deals with drug approvals.
The positive opinion, which will now have to be confirmed by the European Commission, includes two aggressive neoplasms, Acute Lymphoblastic Leukemia (ALL) in B cells in patients up to 25 years of age and diffuse lymphoma Large B-cell (DLBCL) in adults, and in both cases it should be used for forms that do not respond to traditional therapies. Cart-t therapy involves taking the patient's T lymphocytes, a type of immune system cell, to modify them because they recognize the tumor cells and then reinfuse them after replicating them.
"This therapy offers a hope of healing to a group of patients for whom there was no cure before," says Franca Fagioli, president of the Italian Association of Hematology and Dentistry. Pediatric Oncology, to the extent that leukemia could work for those 20% of patients for whom the available medications have no effect, although it should be remembered that it only needs to be administered only in highly specialized centers. "
In Europe, according to a press release from Novartis, which developed the therapy, Lla accounts for about 80% of leukemia cases, while Dlbcl is the most prevalent subtype Non-Hodgkin's lymphoma. "In Italy, it is estimated that 70 to 80 patients with Lla and about 700 for the other pathology could benefit from the therapy – explains Paolo Corradini, president of the Italian Society of Hematology – but Car-t is the first antineoplastic cell therapy in the history of humanity, this approval is the first of a long series, because there are promising experiments for many other indications. "